Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cannabis Derivative Sativex 'Shows Promise In US Patients' Despite Further Phase III Failure

This article was originally published in Scrip

Executive Summary

'No surprise' apparently, as GW Pharmaceuticals and Otsuka Pharmaceutical Development & Commercialization, Inc. report negative top-line results from the remaining two Phase III trials of their cannabis extract product Sativex (nabiximols) for the treatment of pain in advanced cancer patients who experience inadequate analgesia during optimized chronic opioid therapy.

You may also be interested in...



Deal Watch: Vertex Selects First Candidate Under CRISPR Gene-Editing Collaboration

Vertex hopes to develop CTX001 as a treatment for sickle cell disease and beta thalassemia. Allergan adds stalled uterine fibroid candidate in buyout of troubled Repros, Juno licenses multiple myeloma candidate from Lilly.

Interview: GW Pharma Gears Up For Pivotal 2018

The UK group has raised nearly $320m this week which will be used to build commercial organizations in the US and Europe ahead of potential approvals for its cannabinoid epilepsy therapy Epidiolex.

Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well

Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel